Updates on Tumor Mutational Burden and the Immunotherapy Biomarker Landscape


Laura Tafe, M.D.


Jonathan Nowak, M.D.,Ph.D.

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.

Please note that this content was created in 2019. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.

AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.


This webinar will act as an overview and update regarding the use of Tumor Mutational Burden (TMB) as a diagnostic and prognostic tool. Advances in massively parallel sequencing technologies has facilitated the large scale examination of the mutational profile of tumors. Best practices with regard to elaboration of these techniques is evolving as is the correlation of results with clinical outcomes. This presentation will provide additional information regarding the newest innovations as well as implications for TMB testing, interpretation, and reporting. Some clinical applications and challenges will be discussed.

Learning Objectives:

  • Elaborate on the advantages and limitations of TMB molecular diagnostic results.
  • Describe the current use of TMB to guide diagnosis and treatment.
  • Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.

Recording Date: June 6, 2019
Duration: 1 hr
Level of Instruction: Basic
CE Credit for this course has expired.

This webinar is part 1 of a two-part series exploring the role of TMB testing in relationship to other tumor biomarkers as well as the standardization of TMB testing.

For more information on this series, please go here.

AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.